Sympathomimetics

Beta-Adrenergic Agonists

Beta1-adrenergic agonists (dopamine, dobutamine, prenalterol, xamoterol) have been used to treat acute and chronic heart failure, but have limited usefulness in chronic CHF because of their arrhythmogenic effects, short duration of action, the development of tolerance, and necessity of parenteral administration

Dopamine (i.v.) is used in acute heart failure (cardiogenic shock) to increase blood pressure and increase cardiac output

• It has a short half-life (1 min)
• At high doses dopamine has potent peripheral vasoconstrictor effects (alpha-receptor stimulation), in addition to its inotropic effects
• Low dose dopamine has a renal artery dilating effect and may improve sodium and water excretion in patients refractory to loop diuretics
• When systolic pressure is greater than 90 mm Hg, nitroprusside can be added to reduce ventricular filling pressure and reduce afterload
• i.v. furosemide should also be administered to reduce edema

Levodopa and ibopamine, analogs of dopamine that can be administered orally, have been shown to improve symptoms in some patients, but can exhibit arrhythmogenic side-effects and tachyphylaxis

Dobutamine is a somewhat selective beta1-adrenergic agonist that lacks vasoconstrictor activity and causes minimal changes in heart rate

• It is frequently added to nitroprusside when blood pressure is adequate to increase cardiac output
• It is administered as an i.v. infusion to treat acute severe heart failure
• It has a short half-life (2.4 min) and is only used on a short-term basis, although long-term beneficial effects on cardiac function have been noted
• After 72 hours of therapy, tolerance can develop to dobutamine necessitating switch to other inotropic support (e.g. milrinone)
• Dobutamine can enhance AV conduction and worsen atrial tachycardia

Prenalterol and xamoterol are partial beta1-adrenergic agonists that may simultaneously stimulate beta1-receptors and block the receptors from stimulation by endogenous catecholamines, thereby protecting against beta1-receptor down-regulation

Local anesthetic selection

Local anesthetics are typically divided into 3 main categories:

short, intermediate and long acting local anesthetics.

Based on duration of the procedure and the duration of the individual agents

Short acting agents

1. Mepivacaine 3 %

2. Lidocaine 2%

Intermediate acting agents

1. Lidocaine 2% 1:100000 epi

2. Lidocaine 2% 1:50000 epi

3. Mepivacaine 2% 1:20000 neocobefrin

4. Prilocaine 4%

5. Articaine 4% 1:100000 epi

Long acting agents

1. Bupivacaine 0.5% 1:200000 epi

Local Anesthetics

1. Procaine (Novocaine)

a) Classic Ester type agent, first synthetic injectable local anesthetic.

 b) Slow onset and short duration of action

 2. Tetracaine (Pontocaine)

a) Ester type agent--ten times as potent and toxic as procaine.

 b) Slow onset but long duration of action.

 c) Available in injectable and topical applications.

 3. Propoxycaine (Ravocaine)

a) Ester type agent–five times as potent and toxic as procaine.

 b) Often combined with procaine to increase duration of action.

 4. Lidocaine (Xylocaine)

a) Versatile widely used amide type agent.

 b) Two - three times as potent and toxic as procaine.

 c) Rapid onset and relatively long duration of action.

 d) Good agent for topical application.

 5. Mepivacaine (Carbocaine)

a) Amide type agent similar to lidocaine.

 b) Without vasoconstrictor has only short duration of action.

6. Prilocaine (Citanest)

a) Amide type agent — less potent than lidocaine.

 b) Without vasoconstrictor has only short duration of action.

 c) Metabolized to o-toluidine which can cause methemoglobinemia — significant only with large doses of prilocaine.

 d) Higher incidences of paresthesia reported with 4 % preparation

7. Bupivacaine (Marcaine)

a) Amide type agent of high potency and toxicity.

 b) Rapid onset and very long duration of action even without vasoconstrictor.

 8. Articaine (Septocaine)

a) Amide type agent

 b) Only amide-type local anesthetic that contains an ester group, therefore metabolized both in the liver and plasma.

 c) Approved by the FDA in 2000

 d) Evidence points to improved diffusion through hard and soft tissues as compared to other local anesthetics.

 e) Reports of a higher incidence of paresthesia, presumably due to the 4% concentration

 f) Not recommended for use in children under 4 years of age

Propofol -Intravenous Anesthetics

- A nonbarbiturate anesthetic
- It is very lipid-soluble, acts rapidly and has a short recovery time.
- It is associated with less nausea and vomiting than some of the other IV anesthetics.
- Propofol is very similar to thiopental in its effects on the cardiorespiratory system.
- It does not have any analgesic properties but lowers the dose of opioid needed when the two agents are used in combination.

- The most significant adverse cardiovascular effect associated with propofol administration is hypotension. It should be used with caution in patients with cardiac disease.

Stages of anesthesia

Stage I

Analgesia

Still conscious but drowsy

Stage II

Excitement stage

Loss of consciousness, however, irregular ventilation may be present which affects absorption of inhalation agents.

Reflexes may be exaggerated.

This is a very dangerous stage

Stage III

Surgical anesthesia

Loss of spontaneous movement

Regular, shallow respiration

Relaxation of muscles

Stage IV

Medullary paralysis

Death

Thrombolytic Agents:

Tissue Plasminogen Activator (t-PA, Activase)

t-PA is a serine protease. It is a poor plasminogen activator in the absence of fibrin. t-PA binds to fibrin and activates bound plasminogen several hundred-fold more rapidly than it activates plasminogen in the circulation.

Streptokinase (Streptase)

Streptokinase is a protein produced by β-hemolytic streptococci. It has no intrinsic enzymatic activity, but forms a stable noncovalent 1:1 complex with plasminogen. This produces a conformational change that exposes the active site on plasminogen that cleaves a peptide bond on free plasminogen molecules to form free plasmin.

Urokinase (Abbokinase)

Urokinase is isolated from cultured human cells.Like streptokinase, it lacks fibrin specificity and therefore readily induces a systemic lytic state. Like t-PA, Urokinase is very expensive.

Contraindications to Thrombolytic Therapy:

• Surgery within 10 days, including organ biopsy, puncture of noncompressible vessels, serious trauma, cardiopulmonary resuscitation.

• Serious gastrointestinal bleeding within 3 months.

• History of hypertension (diastolic pressure >110 mm Hg).

• Active bleeding or hemorrhagic disorder.

• Previous cerebrovascular accident or active intracranial bleeding.

Aminocaproic acid:

Aminocaproic acid prevents the binding or plasminogen and plasmin to fibrin. It is a potent inhibitor for fibrinolysis and can reverse states that are associated with excessive fibrinolysis.